Patents by Inventor Todd M. Herrington
Todd M. Herrington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8206723Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.Type: GrantFiled: April 1, 2009Date of Patent: June 26, 2012Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7723480Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: March 26, 2008Date of Patent: May 25, 2010Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7705124Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: March 24, 2008Date of Patent: April 27, 2010Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7705125Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: March 27, 2008Date of Patent: April 27, 2010Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7691974Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: March 25, 2008Date of Patent: April 6, 2010Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7671177Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: March 28, 2008Date of Patent: March 2, 2010Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Publication number: 20090202591Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.Type: ApplicationFiled: April 1, 2009Publication date: August 13, 2009Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7534863Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.Type: GrantFiled: January 8, 2004Date of Patent: May 19, 2009Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Publication number: 20090118475Abstract: Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In some embodiments, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular ailments and pain.Type: ApplicationFiled: December 30, 2008Publication date: May 7, 2009Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7491799Abstract: Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In some embodiments, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular ailments and pain.Type: GrantFiled: January 14, 2004Date of Patent: February 17, 2009Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Publication number: 20080214781Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: ApplicationFiled: March 25, 2008Publication date: September 4, 2008Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Publication number: 20080194797Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: ApplicationFiled: March 27, 2008Publication date: August 14, 2008Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Publication number: 20080177042Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: ApplicationFiled: March 28, 2008Publication date: July 24, 2008Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Publication number: 20080177041Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: ApplicationFiled: March 26, 2008Publication date: July 24, 2008Inventors: LANCE E. STEWARD, Todd M. Herrington, Kei Roger Aoki
-
Publication number: 20080177037Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: ApplicationFiled: March 24, 2008Publication date: July 24, 2008Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7393925Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: January 19, 2005Date of Patent: July 1, 2008Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 6903187Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: July 21, 2000Date of Patent: June 7, 2005Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Publication number: 20040220386Abstract: Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In some embodiments, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular ailments and pain.Type: ApplicationFiled: January 14, 2004Publication date: November 4, 2004Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Publication number: 20030027752Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.Type: ApplicationFiled: July 20, 2001Publication date: February 6, 2003Applicant: Allergan Sales, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki